重组人干扰素α-2b注射液雾化吸入治疗手足口病患儿的疗效观察

Efficacy observation of aerosol inhalation of recombinant human interferon α-2b injection in treatment of children with hand-foot-and-mouth disease

  • 摘要: 目的 探讨重组人干扰素α-2b注射液雾化吸入治疗儿童手足口病(HFMD)的疗效。 方法 选取HFMD患儿80例,随机分为2组各40例。对照组给予常规治疗,治疗组在常规治疗的基础上加用重组人干扰素α-2b注射液雾化吸入治疗。比较2组临床症状改善情况、血清学指标变化情况。 结果 治疗3、6 d后,治疗组患儿体温分别为(37.20±0.37)、(36.80±0.31)℃, 显著低于对照组的(37.50±0.46)、(37.10±0.29)℃(P<0.05)。治疗3、6 d后,治疗组进食情况、疱疹改善情况显著优于对照组(P<0.05), 治疗组白细胞计数(WBC)、C反应蛋白(CRP)水平均显著低于对照组(P<0.05)。 结论 重组人干扰素α-2b注射液雾化吸入治疗儿童HFMD效果较好,可以缩短临床症状改善时间,改善血清学指标,促进患儿康复。

     

    Abstract: Objective To investigate the efficacy of aerosol inhalation of recombinant human interferon α-2b injection in treatment of children with hand-foot-and-mouth disease(HFMD). Methods Totally 80 children with HFMD were selected and randomly divided into two groups, with 40 cases in each group. Control group was treated with routine treatment, while treatment group was treated with aerosol inhalation of recombinant human interferon α-2b injection based on routine treatment. The improvement of clinical symptoms and change of serum indexes were compared between two groups. Results After 3 and 6 days of treatment, the body temperature of children in the treatment group was(37.20±0.37)℃ and(36.80±0.31)℃, which were significantly lower than(37.50±0.46)℃ and(37.10±0.29)℃ in the control group(P<0.05). After 3 and 6 days of treatment, the improvement of food intake and herpes in the treatment group were significantly better than those in the control group(P<0.05), and the levels of white blood cell count(WBC)and C reactive protein(CRP)were significantly lower than those in the control group(P<0.05). Conclusion Aerosol inhalation of recombinant human interferon α-2b injection is effective in treatment of children with HFMD, which can shorten improvement time of clinical symptoms, improve serum indexes and promote rehabilitation of children.

     

/

返回文章
返回